Protara Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
DEFA14A: Protara Therapeutics Sets Date for 2025 Annual Meeting, Seeks Stockholder Approval on Key Proposals
Protara Therapeutics schedules its 2025 Annual Meeting for June 11, seeking stockholder votes on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.
NASDAQ
Protara Therapeutics is holding its annual meeting of stockholders on June 11, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, executive compensation, and an amendment to the equity incentive plan.
NASDAQ
Protara Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 7, 2024, with proposals including the election of directors, ratification of the accounting firm, approval of executive compensation, and approval of equity incentive and employee stock purchase plans.
NASDAQ
DEF 14A: Protara Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Protara Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 7, 2024, featuring proposals for director elections, auditor ratification, executive compensation, and equity incentive plan approvals.